Alice Lin-Tsing Yu, MD, PhD.
Distinguished Chair Professor, & Co- Director, Institute of Stem Cell and Translational Cancer Research
Chang Gung Memorial Hospital & Chang Gung University
Distinguished Visiting Fellow, Genomics Research Center, Academic Sinica

Office Address:

Institution of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, No. 5, Fu-Sing St., Kuei Shang, Taoyuan 333, Taiwan

Tel: +886-3 328-1200, ext. 5217; Fax: ext. 5214
E-mail: aliceyu@cgmh.org.tw , aliceyu@ucsd.edu
Education:

1968 M.D., National Taiwan University
1969 M.S., Yale University
1973 Ph.D., Microbiology/Immunology, University of Chicago

Focus of Interest:
  • Cancer immunotherapy.
  • Breast cancer stem cell biology.
  • NKT-stimulatory glycolipids as anti-cancer agents and vaccine adjuvants.
Employment Records:

1977-2001 Assistant Professor through Professor of Pediatrics, University of California, San Diego
2001-2003 Professor and Chief, Pediatric Hematology/Oncology, University of California, San Diego
2003-2013 Distinguished Research Fellow and Deputy Director, Genomics Research Center, Academia Sinica
2013-Present Distinguished Chair Professor, Chang Gung Memorial Hospital & Chang Gung University & Co- Director, Center of Stem Cell and Translational Cancer Research

Honor and Awards:
  • 1997 Biotech All-Stars, San Diego Padre, Qualcome Stadium
  • 2001 Recipient of the Year 2000 “Key to Life” Award from the Leukemia & Lymphoma Society
  • 2009 The 19th Wang Min-Ning Memorial Award for Outstanding Contribution to the Development Mediccal Sciene and Technology, National Health and Society
  • 2011 The 55th Academic Award from the Ministry of Education
Selected Publications since 2010:
1.Yu AL*, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B,Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, et al for the Children’s Oncology Group (COG). Anti-GD2 Antibody with GM-CSF, IL2 and Isotretinoin for Neuroblastoma. N Engl J Med 363(14): 1324-1334, 2010.

2. Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni MB, London WB, Chang CH, Yu AL*. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Research 70(20): 7841-50, 2010 .

3. Wu TN, Lin KH, Chang YJ, Huang JR, Cheng JY, Yu AL* and Wong CH*. Avidity of CD1d-ligand-receptor ternary complex contributes to Th1 polarization and anticancer efficacy. PNAS 108(42):17275-80, 2011 .

4. Unguru Y, Joffe S, Fernandez CV, Yu AL. Ethical Issues for Control-Arm Patients After Revelation of Benefits of Experimental Therapy: A Framework Modeled in Neuroblastoma. J Clin Oncol. 10; 31(5):641-6, 2013.

5. Huang YL, Hung JT, Cheung SK, Lee HY, Chu KC, Li ST, Lin YC, Ren CT, Cheng TJ, Hsu TL, Yu AL, Wu CY, Wong CH. Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. PNAS 110(7):2517-22, 2013.

6. Chang WW, Lin RJ, Yu J, Chang WY, Fu CH, Lai AC, Yu JC, Yu AL. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Can Res. 12;15(3):R39, 2013.

7. Chang BM, Lin HH, Su LJ, Lin WD, Lin RJ, Tzeng YK, Lee RT, Lee YC, Yu AL*, and Chang HC*. Highly fluorescent nanodiamonds protein-functionalized for cell labeling and targeting. Advanced Functional Materials. published on line July 22, 2013.